tiprankstipranks
Insmed (INSM)
NASDAQ:INSM
US Market
INSM
Insmed
RESEARCH TOOLSreports
Want to see INSM full AI Analyst Report?

Insmed (INSM) Stock Forecast & Price Target

1,142 Followers
See the Price Targets and Ratings of:

INSM Analyst Ratings

Strong Buy
17Ratings
Strong Buy
17 Buy
0 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Insmed
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

INSM Stock 12 Month Forecast

Average Price Target

$200.88
▲(39.03% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Insmed in the last 3 months. The average price target is $200.88 with a high forecast of $243.00 and a low forecast of $160.00. The average price target represents a 39.03% change from the last price of $144.48.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"70":"$70","157":"$157","244":"$244","113.5":"$113.5","200.5":"$200.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":243,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$243.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":200.875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$200.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":160,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$160.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[70,113.5,157,200.5,244],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,133.26,141.70153846153846,150.1430769230769,158.58461538461538,167.02615384615385,175.4676923076923,183.90923076923076,192.35076923076923,200.7923076923077,209.23384615384614,217.67538461538462,226.11692307692306,234.55846153846153,{"y":243,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,133.26,138.46115384615385,143.66230769230768,148.86346153846154,154.06461538461537,159.26576923076922,164.46692307692308,169.6680769230769,174.86923076923077,180.07038461538463,185.27153846153846,190.4726923076923,195.67384615384617,{"y":200.875,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,133.26,135.31692307692308,137.37384615384616,139.43076923076922,141.4876923076923,143.54461538461538,145.60153846153847,147.65846153846152,149.7153846153846,151.7723076923077,153.82923076923078,155.88615384615383,157.94307692307692,{"y":160,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":72.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.62,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147.28,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":189.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":211.41,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.04,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.98,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.32,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.86,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.26,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$243.00Average Price Target$200.88Lowest Price Target$160.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on INSM
Danielle Brill
Truist Financial
Truist Financial
$185
Buy
28.05%
Upside
Reiterated
05/18/26
Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Astrana Health (NASDAQ: ASTH) and Baxter International (NYSE: BAX)
UBS Analyst forecast on INSM
Ashwani Verma
UBS
UBS
$166
Buy
14.89%
Upside
Reiterated
05/18/26
Ashwani Verma Reiterates Buy on Insmed as Brinsupri’s Measured but Durable Launch Underpins Long-Term Growth Potential
William Blair Analyst forecast on INSM
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
05/18/26
Analyst Reaffirms Buy on Insmed, Citing Strong ENCORE Phase IIIb Arikayce Data and TPIP IPF Upside
Evercore ISI Analyst forecast on INSM
Unknown Analyst
Evercore ISI
Not Ranked
Evercore ISI
$208→$162
Buy
12.13%
Upside
Reiterated
05/15/26
Evercore ISI Sticks to Their Buy Rating for Insmed (INSM)
Bank of America Securities Analyst forecast on INSM
Jason Zemansky
Bank of America Securities
Bank of America Securities
$214
Buy
48.12%
Upside
Reiterated
05/13/26
Bank of America Securities Sticks to Its Buy Rating for Insmed (INSM)
Barclays Analyst forecast on INSM
Eliana Merle
Barclays
Barclays
$237
Buy
64.04%
Upside
Assigned
05/11/26
Barclays Reaffirms Their Buy Rating on Insmed (INSM)
Jefferies Analyst forecast on INSM
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$185
Buy
28.05%
Upside
Reiterated
05/08/26
Jefferies Remains a Buy on Insmed (INSM)
H.C. Wainwright Analyst forecast on INSM
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$220
Buy
52.27%
Upside
Reiterated
05/08/26
Insmed earnings selloff a buying opportunity, says H.C. WainwrightInsmed earnings selloff a buying opportunity, says H.C. Wainwright
Raymond James Analyst forecast on INSM
Tiago Fauth
Raymond James
Raymond James
$200→$185
Buy
28.05%
Upside
Reiterated
05/08/26
Insmed price target lowered to $185 from $200 at Raymond JamesInsmed price target lowered to $185 from $200 at Raymond James
Stifel Nicolaus Analyst forecast on INSM
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$208→$200
Buy
38.43%
Upside
Reiterated
05/08/26
Stifel Nicolaus Remains a Buy on Insmed (INSM)
Roth MKM Analyst forecast on INSM
Adam Walsh
Roth MKM
Roth MKM
$212
Buy
46.73%
Upside
Reiterated
05/08/26
Insmed pullback a buying opportunity, says Roth CapitalInsmed pullback a buying opportunity, says Roth Capital
Wells Fargo Analyst forecast on INSM
Benjamin Burnett
Wells Fargo
Wells Fargo
$177→$160
Buy
10.74%
Upside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA), Enovis (NYSE: ENOV) and Insmed (NASDAQ: INSM)
TD Cowen Analyst forecast on INSM
Ritu Baral
TD Cowen
TD Cowen
$243
Buy
68.19%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME) and Insmed (NASDAQ: INSM)
RBC Capital Analyst forecast on INSM
Leonid Timashev
RBC Capital
RBC Capital
$220→$205
Buy
41.89%
Upside
Reiterated
05/07/26
RBC Capital Sticks to Their Buy Rating for Insmed (INSM)
Guggenheim Analyst forecast on INSM
Vamil Divan
Guggenheim
Guggenheim
$230→$226
Buy
56.42%
Upside
Reiterated
05/07/26
Insmed (INSM) Receives a Buy from Guggenheim
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on INSM
Danielle Brill
Truist Financial
Truist Financial
$185
Buy
28.05%
Upside
Reiterated
05/18/26
Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Astrana Health (NASDAQ: ASTH) and Baxter International (NYSE: BAX)
UBS Analyst forecast on INSM
Ashwani Verma
UBS
UBS
$166
Buy
14.89%
Upside
Reiterated
05/18/26
Ashwani Verma Reiterates Buy on Insmed as Brinsupri’s Measured but Durable Launch Underpins Long-Term Growth Potential
William Blair Analyst forecast on INSM
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
05/18/26
Analyst Reaffirms Buy on Insmed, Citing Strong ENCORE Phase IIIb Arikayce Data and TPIP IPF Upside
Evercore ISI Analyst forecast on INSM
Unknown Analyst
Evercore ISI
Not Ranked
Evercore ISI
$208→$162
Buy
12.13%
Upside
Reiterated
05/15/26
Evercore ISI Sticks to Their Buy Rating for Insmed (INSM)
Bank of America Securities Analyst forecast on INSM
Jason Zemansky
Bank of America Securities
Bank of America Securities
$214
Buy
48.12%
Upside
Reiterated
05/13/26
Bank of America Securities Sticks to Its Buy Rating for Insmed (INSM)
Barclays Analyst forecast on INSM
Eliana Merle
Barclays
Barclays
$237
Buy
64.04%
Upside
Assigned
05/11/26
Barclays Reaffirms Their Buy Rating on Insmed (INSM)
Jefferies Analyst forecast on INSM
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$185
Buy
28.05%
Upside
Reiterated
05/08/26
Jefferies Remains a Buy on Insmed (INSM)
H.C. Wainwright Analyst forecast on INSM
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$220
Buy
52.27%
Upside
Reiterated
05/08/26
Insmed earnings selloff a buying opportunity, says H.C. WainwrightInsmed earnings selloff a buying opportunity, says H.C. Wainwright
Raymond James Analyst forecast on INSM
Tiago Fauth
Raymond James
Raymond James
$200→$185
Buy
28.05%
Upside
Reiterated
05/08/26
Insmed price target lowered to $185 from $200 at Raymond JamesInsmed price target lowered to $185 from $200 at Raymond James
Stifel Nicolaus Analyst forecast on INSM
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$208→$200
Buy
38.43%
Upside
Reiterated
05/08/26
Stifel Nicolaus Remains a Buy on Insmed (INSM)
Roth MKM Analyst forecast on INSM
Adam Walsh
Roth MKM
Roth MKM
$212
Buy
46.73%
Upside
Reiterated
05/08/26
Insmed pullback a buying opportunity, says Roth CapitalInsmed pullback a buying opportunity, says Roth Capital
Wells Fargo Analyst forecast on INSM
Benjamin Burnett
Wells Fargo
Wells Fargo
$177→$160
Buy
10.74%
Upside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA), Enovis (NYSE: ENOV) and Insmed (NASDAQ: INSM)
TD Cowen Analyst forecast on INSM
Ritu Baral
TD Cowen
TD Cowen
$243
Buy
68.19%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME) and Insmed (NASDAQ: INSM)
RBC Capital Analyst forecast on INSM
Leonid Timashev
RBC Capital
RBC Capital
$220→$205
Buy
41.89%
Upside
Reiterated
05/07/26
RBC Capital Sticks to Their Buy Rating for Insmed (INSM)
Guggenheim Analyst forecast on INSM
Vamil Divan
Guggenheim
Guggenheim
$230→$226
Buy
56.42%
Upside
Reiterated
05/07/26
Insmed (INSM) Receives a Buy from Guggenheim
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Insmed

3 Months
xxx
Success Rate
13/17 ratings generated profit
76%
Average Return
+26.05%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 76.47% of your transactions generating a profit, with an average return of +26.05% per trade.
1 Year
Joseph SchwartzLeerink Partners
Success Rate
18/20 ratings generated profit
90%
Average Return
+88.02%
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +88.02% per trade.
2 Years
xxx
Success Rate
18/20 ratings generated profit
90%
Average Return
+178.85%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +178.85% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

INSM Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
1
2
6
8
22
Buy
35
49
40
45
30
Hold
4
5
5
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
40
56
51
55
53
In the current month, INSM has received 52 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. INSM average Analyst price target in the past 3 months is 200.88.
Each month's total comprises the sum of three months' worth of ratings.

INSM Financial Forecast

INSM Earnings Forecast

Next quarter’s earnings estimate for INSM is -$0.80 with a range of -$1.35 to -$0.58. The previous quarter’s EPS was -$0.76. INSM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year INSM has Performed in-line its overall industry.
Next quarter’s earnings estimate for INSM is -$0.80 with a range of -$1.35 to -$0.58. The previous quarter’s EPS was -$0.76. INSM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year INSM has Performed in-line its overall industry.

INSM Sales Forecast

Next quarter’s sales forecast for INSM is $391.17M with a range of $359.30M to $414.37M. The previous quarter’s sales results were $305.96M. INSM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year INSM has Performed in-line its overall industry.
Next quarter’s sales forecast for INSM is $391.17M with a range of $359.30M to $414.37M. The previous quarter’s sales results were $305.96M. INSM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year INSM has Performed in-line its overall industry.

INSM Stock Forecast FAQ

What is INSM’s average 12-month price target, according to analysts?
Based on analyst ratings, Insmed’s 12-month average price target is 200.88.
    What is INSM’s upside potential, based on the analysts’ average price target?
    Insmed has 39.03% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is INSM a Buy, Sell or Hold?
          Insmed has a consensus rating of Strong Buy which is based on 17 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Insmed’s price target?
            The average price target for Insmed is 200.88. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $243.00 ,the lowest forecast is $160.00. The average price target represents 39.03% Increase from the current price of $144.48.
              What do analysts say about Insmed?
              Insmed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of INSM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.